Bevacizumab Treatment and Retinal Vessel Monitoring (BevaRet)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00740168
Recruitment Status : Completed
First Posted : August 22, 2008
Last Update Posted : January 21, 2016
Information provided by (Responsible Party):
Technische Universität Dresden

Brief Summary:
Bevacizumab might influence the dynamic vessel function after being administered intravenously.

Condition or disease Intervention/treatment
Cancer Drug: bevacizumab treatment

Detailed Description:
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy
Study Start Date : May 2007
Actual Primary Completion Date : December 2008
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Group/Cohort Intervention/treatment
Bevacizumab treatment group with metastasized cancer
Drug: bevacizumab treatment
single infusion 10 mg/kg
Other Names:
  • Avastin
  • ATC code: L01XC07
  • CAS Registry Number:216974-75-3
  • VEGF-inhibitor

Primary Outcome Measures :
  1. Diameter of retinal vessels and dynamic vessel reaction [ Time Frame: Measurements before and after administration ]

Secondary Outcome Measures :
  1. Baroreflex sensitivity, heart frequence variability, reaction to handgrip test [ Time Frame: Measurements before and after administration ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cancer patients with first bevacizumab treatment

Inclusion Criteria:

  • patients who wish and need bevacizumab treatment for underlying disease

Exclusion Criteria:

  • previous bevacizumab treatment
  • known eye disease, eye surgery or eye trauma in history
  • myopia >-2.0 dpt
  • hyperopia > +2.0 dpt.
  • relevant media opacity of the lens
  • acute heart disease, ischemic insult, proven coronary heart disease
  • cardiac arrhythmia or vessel anomalies
  • seizure disorder or episode in history
  • migraine
  • treatment with corticosteroids within 4 weeks before study inclusion
  • intake of vasoactive drugs like AT-1 or glitazone
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00740168

Autonomic lab (ANF)
Dresden, Sachsen, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Principal Investigator: Tjalf Ziemssen, MD Neurological University Clinic

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Technische Universität Dresden Identifier: NCT00740168     History of Changes
Other Study ID Numbers: B-ANF1
First Posted: August 22, 2008    Key Record Dates
Last Update Posted: January 21, 2016
Last Verified: January 2016

Keywords provided by Technische Universität Dresden:

Additional relevant MeSH terms:
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents